Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863206 | 0.87 | KMT2A (0.39) | KMT2AKDM4ESMN1; SMN2MAPK8ADORA3 | |
| SCHEMBL5863203 | 0.87 | KMT2A (0.39) | KMT2AKDM4ESMN1; SMN2MAPK8ADORA3 | |
| SCHEMBL5863148 | 0.80 | KIF11 (0.44) | KMT2AKDM4ESMN1; SMN2MAPK8ADORA3 | |
| SCHEMBL5863079 | 0.79 | KIF11 (0.44) | KDM4ESMN1; SMN2ADORA3ALDH1A1MAPT | |
| SCHEMBL5863407 | 0.76 | TSHR (0.52) | KMT2AKDM4ESMN1; SMN2ADORA3ALDH1A1 | |
| SCHEMBL5863656 | 0.76 | KIF11 (0.41) | KMT2AKDM4ESMN1; SMN2MAPK8ADORA3 | |
| SCHEMBL13120820 | 0.68 | MAPK8 (0.49) | KMT2AKDM4ESMN1; SMN2MAPK8AR | |
| SCHEMBL5863118 | 0.67 | KIF11 (0.44) | KDM4ESMN1; SMN2ADORA3ALDH1A1MAPT | |
| SCHEMBL5863114 | 0.67 | KIF11 (0.44) | KDM4ESMN1; SMN2ADORA3ALDH1A1MAPT | |
| SCHEMBL14452607 | 0.66 | BRD4 (0.56) | KMT2AKDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030118-B2 | Pyrrolotriazinone compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232832-A1 | Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents | CCNB1, NUMA1, CCNA1 | KMT2A 325/4885KDM4E 1096/4885SMN1; SMN2 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.